drugset / Trial / NCT00210002

Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

NCT00210002

Phase 2 Terminated 55 enrolled Institut Claudius Regaud
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the response rate obtained in an heterogeneous oncologic population treated by chemotherapy, and either by Darbepoetin alfa classic treatment or by association of Darbepoetin alfa -ferric saccharose systematic supplementation, administered concomitantly with chemotherapy.

Timeline

Start
2003-11
Primary completion
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic
Subject Ferric saccharose Unknown

Indications